EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry

Patrick Deegan iD, Heather Lau iD, Deborah Elstein iD, Diego Fernandez-Sasso, Pilar Giraldo iD, Derralynn Hughes, Ari Zimran iD, Majdolen Istaiti iD, Noga Gadir, Jaco Botha, Shoshana Revel-Vilk iD, GOS Study Group

Journal of Clinical Medicine · 09.05.2024 · 13 (10) · 2782

DOI: 10.3390/jcm13102782 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 09.05.2024. Verfasst von Patrick Deegan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Lysosomal Disorders Unit, Cambridge University Hospitals, Hills Road, Cambridge CB2 0QQ, UK. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda (Switzerland), Takeda Pharmaceuticals International AG, Zurich, Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gaucher disease (GD) is a rare, autosomal, recessive condition characterized by hepatosplenomegaly, thrombocytopenia, anemia, and bone abnormalities, often requiring life-long treatment. Velaglucerase alfa has improved hematologic and visceral parameters in clinical trials; however, limited long-term efficacy and safety data are available.

Methods

The Gaucher Outcome Survey (GOS), a structured and validated international registry for patients with confirmed GD, provides an opportunity to evaluate long-term data from patients receiving velaglucerase alfa.

Results

This analysis included 376 treatment-naïve children and adults with GD enrolled in GOS, including 20 with type 3 GD, who initiated velaglucerase alfa through participation in clinical trials or as part of their clinical management and continued treatment for a mean (range) time of 6.6 (0.003–18.6) years. Initial improvements in hematologic and visceral parameters and the biomarkers glucosylsphingosine (lyso-GL1) and chitotriosidase were observed after one year of treatment and were maintained throughout the follow-up period. Of 129 (34.3%) patients who developed adverse events during the follow-up period, events were considered related to treatment in 33 (8.8%). None led to treatment discontinuation. There were 21 deaths overall, none of which were considered related to treatment.

Conclusions

This analysis of data from the GOS registry supports the safety and efficacy of velaglucerase alfa in patients with GD.

Schlagwörter

Stichwörter der Autor:innen

ERTGOSGaucher diseaseenzyme replacement therapylong termregistryvelaglucerase alfa

Autor:innen und Institutionen

  • Lysosomal Disorders Unit, Cambridge University Hospitals, Hills Road, Cambridge CB2 0QQ, UK.
  • Langone Medical Center, New York University, 333 E 33rd St, New York, NY 10016, USA.
  • Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, 8152 Zurich, Switzerland.
  • Instituto William Osler, Paraguay 2935, Buenos Aires C1425 BRI, Argentina.
  • En el Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, IIS Aragon, C. de San Juan Bosco 13, 50009 Zaragoza, Spain.
  • Translational Research Unit, IIS Aragon, Paseo de Isabel la Católica 1-3, 50009 Zaragoza, Spain.

ORCID-Profile: Patrick Deegan, Heather Lau, Deborah Elstein, Pilar Giraldo, Ari Zimran, Majdolen Istaiti, Shoshana Revel-Vilk

Förderung

  • Takeda (Switzerland)
  • Takeda Pharmaceuticals International AG, Zurich, Switzerland

Zitieren

APA

Deegan, P., Lau, H., Elstein, D., Fernandez-Sasso, D., Giraldo, P., Hughes, D., Zimran, A., Istaiti, M., Gadir, N., Botha, J., Revel-Vilk, S., & GOS Study Group (2024). Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry. Journal of Clinical Medicine, 13(10), 2782. https://doi.org/10.3390/jcm13102782

Vancouver

Deegan P, Lau H, Elstein D, Fernandez-Sasso D, Giraldo P, Hughes D, et al. Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry. Journal of Clinical Medicine. 2024;13(10):2782. doi:10.3390/jcm13102782

BibTeX
@article{Deegan2024,
  author = {Deegan, Patrick and Lau, Heather and Elstein, Deborah and Fernandez-Sasso, Diego and Giraldo, Pilar and Hughes, Derralynn and Zimran, Ari and Istaiti, Majdolen and Gadir, Noga and Botha, Jaco and Revel-Vilk, Shoshana and GOS Study Group, GOS Study Group},
  title = {Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {10},
  pages = {2782},
  doi = {10.3390/jcm13102782}
}
Kostenlos starten →